| 9.17 0.62 (7.25%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 12.29 |
1-year : | 14.36 |
| Resists | First : | 10.52 |
Second : | 12.29 |
| Pivot price | 8.54  |
|||
| Supports | First : | 8.41 |
Second : | 7.09 |
| MAs | MA(5) : | 8.4 |
MA(20) : | 8.57 |
| MA(100) : | 8.06 |
MA(250) : | 9.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 34.9 |
D(3) : | 25.2 |
| RSI | RSI(14): 59 |
|||
| 52-week | High : | 17.57 | Low : | 5.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNA ] has closed below upper band by 19.9%. Bollinger Bands are 23.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.21 - 9.25 | 9.25 - 9.28 |
| Low: | 8.57 - 8.61 | 8.61 - 8.65 |
| Close: | 9.1 - 9.17 | 9.17 - 9.23 |
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
Thu, 18 Jun 2026
DNA Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 18 Jun 2026
Ginkgo Bioworks Holdings Inc (DNA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Thu, 18 Jun 2026
Ginkgo Bioworks Holdings Inc - TradingKey
Mon, 15 Jun 2026
Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant - Stock Titan
Mon, 15 Jun 2026
Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Mon, 15 Jun 2026
Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 68.6 (%) |
| Shares Short | 4,560 (K) |
| Shares Short P.Month | 5,230 (K) |
| EPS | -5.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.19 |
| Profit Margin | -201.1 % |
| Operating Margin | -366.6 % |
| Return on Assets (ttm) | -16.2 % |
| Return on Equity (ttm) | -56.1 % |
| Qtrly Rev. Growth | -49.1 % |
| Gross Profit (p.s.) | 1.97 |
| Sales Per Share | 2.83 |
| EBITDA (p.s.) | -4.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -166 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -1.71 |
| PEG Ratio | 0 |
| Price to Book value | 1.27 |
| Price to Sales | 3.23 |
| Price to Cash Flow | -2.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|